白细胞增多是局部晚期头颈癌放化疗后的预后生物标志物
该回顾性队列纳入2006年3月至2012年10月在本院接受顺铂同步放疗的193例局部晚期头颈鳞癌患者,24%存在基线白细胞增多、20%存在中性粒细胞增多。单因素分析显示白细胞增多和中性粒细胞增多均与较差的总生存和无进展生存强相关(p<0.001),多因素分析中N分期、HPV/p16、吸烟状态和白细胞增多与较差OS和PFS相关。
要点
- 基线白细胞增多(>10 G/L)和中性粒细胞增多(>7.5 G/L)分别见于24%和20%的局部晚期头颈鳞癌患者。
- 单因素分析中白细胞增多和中性粒细胞增多均与较差OS和PFS强相关(p<0.001)。
- 多因素分析中N分期、HPV/p16、吸烟状态和白细胞增多与较差OS和PFS相关。
核心结论
- 在接受顺铂同步放疗的局部晚期头颈鳞癌患者中,基线白细胞增多可预测总生存和无进展生存。
- 结合HPV状态,这一独立生物标志物可能有助于识别肿瘤复发高风险患者。
研究设计与样本
- 回顾性队列研究,收集2006年3月至2012年10月在本院连续收治的既往未治疗局部晚期头颈鳞癌患者临床记录。
- 共纳入193例患者,均接受顺铂(100 mg/m2,每3周一次)同步放疗(70 Gy,7周)。
- 白细胞增多定义为白细胞计数超过10 G/L,中性粒细胞增多定义为中性粒细胞计数超过7.5 G/L。
主要发现
- 分别有24%和20%的患者存在基线白细胞增多或中性粒细胞增多。
- 当前吸烟者、体能状态(PS)>0者、T4患者的平均白细胞计数显著更高,HPV阳性肿瘤患者更低。
- 5年实际总生存(OS)和无进展生存(PFS)分别为56%和51%。
- 单因素分析中,白细胞增多和中性粒细胞增多均与较差的OS和PFS强相关(p<0.001)。
- 多因素分析中,N分期、HPV/p16、吸烟状态和白细胞增多与较差的OS和PFS相关;顺铂周期数<3的患者生存更差。
关键数值与推荐
- 白细胞增多定义为白细胞计数>10 G/L;中性粒细胞增多定义为中性粒细胞计数>7.5 G/L。
- 顺铂剂量为100 mg/m2,每3周一次;放疗剂量为70 Gy,7周。
- 193例患者中24%有基线白细胞增多,20%有基线中性粒细胞增多。
- 5年实际OS为56%,5年实际PFS为51%。
- 单因素分析中白细胞增多和中性粒细胞增多与OS和PFS的关联p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the prognostic value of leukocyte increase in a retrospective cohort of locally advanced head and neck squamous cell carcinoma (HNSCC) patients receiving definitive concurrent cisplatin and radiation. MATERIALS AND METHODS: Clinical records of consecutive previously untreated locally advanced HNSCC patients treated in our Institution between March 2006 and October 2012 by concurrent cisplatin (100 mg/m2, every 3 weeks) and radiation (70 Gy in 7 weeks) were collected. The prognostic value of pretreatment leukocyte increase was examined, with focus on patterns of relapse and survival. Leukocytosis and neutrophilia were defined as a leukocyte count or a neutrophils count exceeding 10 and 7.5 G/L, respectively. RESULTS: We identified 193 patients, all treated with concurrent cisplatin-based chemoradiotherapy. Respectively 24% and 20% patients displayed baseline leukocytosis or neutrophilia. Mean leukocyte count were significantly more elevated in current smokers, patients with performance status (PS) >0, T4 and less in HPV + tumor. The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 56% and 51% respectively. In univariate analysis, both leukocytosis and neutrophilia were strongly associated with worse OS and PFS (p < 0.001). In multivariate analysis, N classification, HPV/p16, smoking status and leukocytosis were associated with worse OS and PFS. Patients with <3 cycles of cisplatin had worse survival. CONCLUSION: In locally advanced HNSCC treated with concurrent cisplatin and radiation, baseline leukocytosis predicts OS and PFS. In addition with HPV status, this independent biomarker could help identifying patients with high risk of tumor relapse.
引用
- Schernberg A, Blanchard P, Chargari C, et al. Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. Clin Transl Radiat Oncol. 2018. PMID: 30073209. doi:10.1016/j.ctro.2018.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。